In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.
Phase:
PHASE2
Details
Lead Sponsor:
University of Illinois at Chicago
Collaborators:
National Eye Institute (NEI) National Institutes of Health (NIH)